Search results for "Tatin"

showing 10 items of 700 documents

First total synthesis of antiostatin A1, a potent carbazole-based naturally occurring antioxidant.

2009

The first total synthesis of the potent antioxidant antiostatin A1 is reported, where its key features rely on a chemo- and regioselective rhodium-catalysed crossed alkyne cyclotrimerisation reaction applying functionalised ynamides and a palladium-catalysed arylamidation reaction.

Antioxidantmedicine.medical_treatmentCarbazolesAlkyneAntioxidantsCatalysischemistry.chemical_compoundAntiostatin A1Materials ChemistrymedicineOrganic chemistryRhodiumchemistry.chemical_classificationMolecular StructureCarbazoleMetals and AlloysTotal synthesisRegioselectivityStereoisomerismGeneral ChemistryKey featuresSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialschemistryCyclizationCeramics and CompositesPalladiumChemical communications (Cambridge, England)
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatm…

2005

Familial hypercholesterolaemia (FH) is an autosomal dominant disease characterized by elevated levels of low-density lipoprotein-cholesterol (LDL-C). Phenotypic expression is highly variable, being influenced by diet, age, gender, body mass index, apolipoprotein E genotype and type of LDL-receptor gene mutation. Microsomal triglyceride (TG) transfer protein (MTP) is a protein involved in lipid metabolism. Polymorphism MTP -493 GT has been shown to modulate lipid levels in several populations. To analyse the effect of this polymorphism in the lipid phenotype expression of FH and treatment response, we studied a sample of 222 Spanish FH patients, of whom 147 were studied before and after trea…

Apolipoprotein EMaleAtorvastatinPolymerase Chain ReactionMicrosomal triglyceride transfer proteinBody Mass Indexchemistry.chemical_compoundAtorvastatinGeneral Pharmacology Toxicology and PharmaceuticsPromoter Regions GeneticGenetics (clinical)Polymorphism Single-Stranded ConformationalGeneticsbiologyAutosomal dominant traitFastingLipoproteins LDLCholesterolPhenotypeMolecular Medicinelipids (amino acids peptides and proteins)Femalemedicine.drugmedicine.medical_specialtyHeterozygoteGenotypeLipoproteinsHyperlipoproteinemia Type IIApolipoproteins ESex FactorsInternal medicineGeneticsmedicineHumansPyrrolesMolecular BiologyAllelesTriglyceridesPolymorphism GeneticTriglycerideCholesterolGenetic VariationCholesterol LDLDNALipid MetabolismEndocrinologychemistryHeptanoic AcidsPharmacogeneticsMutationbiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsCarrier ProteinsBody mass indexPharmacogeneticsPharmacogenetics and genomics
researchProduct

Cholesterol in Alzheimer’s Disease and other Amyloidogenic Disorders

2010

The complex association of cholesterol metabolism and Alzheimer’s disease is presented in depth, including the possible benefits to be gained from cholesterol-lowering statin therapy. Then follows a survey of the role of neuronal membrane cholesterol in Aβ pore formation and Aβ fibrillogenesis, together with the link with membrane raft domains and gangliosides. The contribution of structural studies to Aβ fibrillogenesis, using TEM and AFM, is given some emphasis. The role of apolipoprotein E and its isoforms, in particular ApoE4, in cholesterol and Aβ binding is presented, in relation to genetic risk factors for Alzheimer’s disease. Increasing evidence suggests that cholesterol oxidation p…

Apolipoprotein Emedicine.medical_specialtyStatinbiologyCholesterolmedicine.drug_classMembrane raftFibrillogenesisDiseasechemistry.chemical_compoundEndocrinologychemistryBiochemistryInternal medicineHMG-CoA reductasemedicinebiology.proteinlipids (amino acids peptides and proteins)Cholesterol metabolism
researchProduct

Oxamidato complexes. Part 4. Electrochemical study of the copper(III)/copper(II) couple in monomeric N,N?-bis(substituent)oxamidatocopper(II) complex…

1993

The electrochemical behaviour of a series of monomeric N,N′-bis(substituent)oxamidato copper(II) complexes of formula Na2[Cu(3,5,3′,5′-X4obbz)]·4H2O [X = Cl (1), Br (2), I (3) and obbz = oxamidobis(benzoato)], Na2-[Cu(obbz)]·4H2O (4), Na2[Cu(5,5′-Me2obbz)]·4H2O (5), Na2[Cu(4,5,4,5′-(MeO)4obbz)]·4H2O(6),Na2[Cu(obp)]· 3.5H2O (7) (obp = oxamidobis(propionato)) and Na2[Cu(pba)]·6H2O (8), [pba = propylenebis(oxamate)] has been investigated by cyclic voltammetry, rotating disk electrode and coulometry in water and dimethylsulphoxide (dmso) solutions. NaNO3 (0.1 M) and n-Bu4NPF6 (0.1 M) were used as supporting electrolytes in H2O and dmso respectively, all solutions being thermostatted at 25 °C. I…

Aqueous solutionLigandOxamideInorganic chemistryMetals and AlloysSubstituentchemistry.chemical_elementMedicinal chemistryCopperInorganic Chemistrychemistry.chemical_compoundchemistryMaterials ChemistryRotating disk electrodeCyclic voltammetryOrganometallic chemistryTransition Metal Chemistry
researchProduct

A Highly Magnetized Twin-Jet Base Pinpoints a Supermassive Black Hole

2016

Supermassive black holes (SMBH) are essential for the production of jets in radio-loud active galactic nuclei (AGN). Theoretical models based on Blandford & Znajek extract the rotational energy from a Kerr black hole, which could be the case for NGC1052, to launch these jets. This requires magnetic fields of the order of $10^3\,$G to $10^4\,$G. We imaged the vicinity of the SMBH of the AGN NGC1052 with the Global Millimetre VLBI Array and found a bright and compact central feature, smaller than 1.9 light days (100 Schwarzschild radii) in radius. Interpreting this as a blend of the unresolved jet bases, we derive the magnetic field at 1 Schwarzschild radius to lie between 200 G and ~8000…

AstrofísicaCamps magnèticsActive galactic nucleus[ PHYS.ASTR ] Physics [physics]/Astrophysics [astro-ph]AstronomyAstrophysics::High Energy Astrophysical Phenomenagalaxies: activeFOS: Physical sciencesAstrophysicsAstrophysics::Cosmology and Extragalactic Astrophysicsmagnetic fields01 natural sciencesGeneral Relativity and Quantum Cosmology0103 physical sciences010303 astronomy & astrophysicsAstrophysics::Galaxy AstrophysicsHigh Energy Astrophysical Phenomena (astro-ph.HE)PhysicsSupermassive black holeJet (fluid)010308 nuclear & particles physicsAstronomy and AstrophysicsRadiusgalaxies: jetsAstrophysics - Astrophysics of GalaxiesMagnetic fieldRotational energyRotating black holeSpace and Planetary ScienceAstrophysics of Galaxies (astro-ph.GA)ComputingMethodologies_DOCUMENTANDTEXTPROCESSINGAstronomiagalaxies: nucleiAstrophysics - High Energy Astrophysical Phenomenagalaxies: magnetic fields[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]Schwarzschild radius
researchProduct

Multifrequency Studies of the Peculiar Quasar 4C +21.35 during the 2010 Flaring Activity

2014

著者人数: 290名

AstrofísicaelectronPhotontorusAstrophysics01 natural scienceslaw.inventiongalaxies: active – gamma rays: general – quasars: general – quasars: individual (4C +21.35) – radiation mechanisms: non-thermalactive gamma rays: general quasars: general quasars: individual: 4C +21.35 radiation mechanisms: non-thermal [galaxies]lawblack hole: Kerrgalaxies: active; gamma rays: general; quasars: general; quasars: individual: 4C +21.35; radiation mechanisms: non-thermalopticalGalaxies: active; Gamma rays: general; Quasars: general; Quasars: individual (4C +21.35); Radiation mechanisms: non-thermal010303 astronomy & astrophysicsastro-ph.HEHigh Energy Astrophysical Phenomena (astro-ph.HE)Physicsenergy: highPhysicsphotonRadiusnon-thermal [radiation mechanisms]Synchrotrongamma ray: emissionactive [galaxies]astro-ph.COElectrónicaFísica nuclearElectricidadGalaxies: active; Gamma rays: general; Quasars: general; Quasars: individual (4C +21.35); Radiation mechanisms: non-thermal; Nuclear and High Energy PhysicsAstrophysics - High Energy Astrophysical Phenomenaquasars: individual (4C +21.35)Astrophysics - Cosmology and Nongalactic AstrophysicsFlareradiation mechanisms: non-thermal; galaxies: active; quasars: general; quasars: individual (4C +21.35); gamma rays: observationsNuclear and High Energy PhysicsCosmology and Nongalactic Astrophysics (astro-ph.CO)astro-ph.GAAstrophysics::High Energy Astrophysical Phenomenaeducationgalaxies: activeFOS: Physical sciencesquasars: individual: 4C +21.35Astrophysics::Cosmology and Extragalactic AstrophysicsVHEGLASTemission: modelTelescopeX-rayquasars: general0103 physical sciencessynchrotrongalaxies: active gamma rays: general quasars: general quasars: individual: 4C +21.35 radiation mechanisms: non-thermalquasarflux: densityindividual: 4C +21.35 [quasars]Astrophysics::Galaxy AstrophysicsAstronomia Observacionsgeneral [quasars]010308 nuclear & particles physicsAstronomy and AstrophysicsQuasargamma rays: generalradiation mechanisms: non-thermalAstrophysics - Astrophysics of GalaxiesMAGICRotating black holeSpace and Planetary SciencegravitationAstrophysics of Galaxies (astro-ph.GA)ddc:520spectral[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]general [gamma rays]Fermi Gamma-ray Space Telescope
researchProduct

Efficacy of Magnetic Resonance Imaging in assessing the Prognosis of Atherosclerotic plaques in patients under Statin Therapy: A Systematic Review of…

2021

The current study aims to conduct a systematic review on the efficacy of Magnetic Resonance Imaging (MRI) in assessing the Prognosis of Atherosclerotic plaques in patients under Statin Therapy. For this purpose, the existing studies focusing on these criteria and the clinical trials and studies have been focused upon. The time frame set for the evaluation of the present literature and findings has been set at the previous decade i.e. the studies of the previous 10 years have been searches through authentic databases and the data related to the current topic has been extracted through efficient sources and reviewers. All the details about MRI efficacy in the assessment of prognosis of Athero…

Atherosclerotic plaquesStatin TherapySystematic ReviewMRISystematic Reviews in Pharmacy
researchProduct

The electron affinity of astatine

2020

One of the most important properties influencing the chemical behavior of an element is the electron affinity (EA). Among the remaining elements with unknown EA is astatine, where one of its isotopes, 211At, is remarkably well suited for targeted radionuclide therapy of cancer. With the At− anion being involved in many aspects of current astatine labeling protocols, the knowledge of the electron affinity of this element is of prime importance. Here we report the measured value of the EA of astatine to be 2.41578(7) eV. This result is compared to state-of-the-art relativistic quantum mechanical calculations that incorporate both the Breit and the quantum electrodynamics (QED) corrections and…

Atomic Physics (physics.atom-ph)ENERGIESGeneral Physics and AstronomyElectron01 natural sciences7. Clean energyPhysics - Atomic PhysicsElectronegativityastatiinielectron affinityPhysics::Atomic Physicslcsh:SciencePhysicsMultidisciplinary010304 chemical physicsIsotopeQELECTRONEGATIVITYMultidisciplinary SciencesHalogenScience & Technology - Other Topicsddc:500Atomic physicsBASIS-SET CONVERGENCE[CHIM.RADIO]Chemical Sciences/RadiochemistryRadioactive decayChemical physicsAstrophysics::High Energy Astrophysical PhenomenaScienceComputer Science::Neural and Evolutionary ComputationOther Fields of PhysicsPOTENTIALSFOS: Physical scienceschemistry.chemical_elementphysics.atom-phGeneral Biochemistry Genetics and Molecular BiologyArticleIonElectron affinity0103 physical sciences[CHIM]Chemical Sciences010306 general physicsAstatineDETECTORScience & TechnologySTABILITYRadiochemistry500General Chemistrychemistrylcsh:Qastatine
researchProduct